
Eczema linked to higher odds of sleep disturbance in children
Eczema was linked to 28% higher odds of sleep disturbance in a 26,395-patient pediatric primary care cohort presented at ACAAI 2026.
Children with atopic dermatitis (AD) seen in an urban primary care setting had modestly but significantly higher odds of a documented sleep disturbance than peers without the condition, according to a retrospective analysis presented at the 2026 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona.¹
The association held whether or not patients also had atopic comorbidities or mental health diagnoses, a finding the investigators said should prompt clinicians to look beyond the skin during routine eczema visits.¹ "This highlights the importance of asking about sleep, not just skin symptoms, when caring for children with eczema," said lead researcher Samantha Sundermeier, DO, an ACAAI member, in a statement.¹
Retrospective EHR study design and sleep disturbance findings in pediatric eczema
Sundermeier and coauthor N. Buboltz reviewed electronic health records for 26,395 patients from birth to age 21 years seen at a single urban primary care clinic between January 2024 and January 2026.¹ The team extracted diagnoses of eczema, sleep disturbance, atopy (such as asthma or allergic rhinitis), and mental health conditions.¹
Eczema was documented in 14.5% of patients and sleep disturbance in 10.3%; 34.9% had an atopic condition and 11.5% a mental health diagnosis.¹ Both eczema and sleep disturbance were recorded in 1.8% of the cohort.¹
Approximately 12% of children with eczema had a sleep disturbance diagnosis, compared with about 10% of those without eczema.¹ Eczema was associated with greater odds of sleep disturbance (odds ratio [OR], 1.28; 95% CI, 1.15-1.42; P < .001).¹ Neither mental health status (P = .46 for effect modification) nor atopy (P = .12) significantly modified the association.¹
Burden of sleep disturbance in children with atopic dermatitis
AD affects an estimated 10% to 20% of US children, and sleep disturbance has consistently been reported in roughly 60% of those affected, rising during flares.² In a cross-sectional survey of 180 parent-child dyads, Fishbein and colleagues estimated that sleep disturbance affects 66.9% (95% CI, 53.3%-80.5%) of US children aged 5 to 17 years with AD, or approximately 3.1 million children.² Itch intensity and lower household income predicted parent-reported sleep disturbance, and poor sleep was associated with depression, anxiety, fatigue, and inattention.² Those investigators recommended screening school-aged children with AD for these symptoms, particularly those with moderate to severe disease.²
Sleep is also treated as a patient-important outcome in AD management. Evidence reviews informing the 2023 AAAAI/ACAAI Joint Task Force on Practice Parameters guideline assessed sleep alongside disease severity, itch, and quality of life,³ and the guideline issued 25 recommendations spanning topical therapy, bleach baths, dietary elimination, allergen immunotherapy, and systemic treatments.⁴
The findings support the investigators' recommendation that clinicians ask families about sleep during eczema visits, because earlier recognition could inform treatment planning.¹ Prospective studies using validated sleep measures and stratified by AD severity would help clarify which children are most at risk.
References
1. American College of Allergy, Asthma and Immunology. Study finds link between eczema and sleep problems in kids. News release. November 12, 2026. Accessed November 18, 2026. https://acaai.org/news/study-finds-link-between-eczema-and-sleep-problems-in-kids/
2. Fishbein AB, Cheng BT, Tilley CC, et al. Sleep disturbance in school-aged children with atopic dermatitis: prevalence and severity in a cross-sectional sample. J Allergy Clin Immunol Pract. 2021;9(8):3120-3129.e3. doi:10.1016/j.jaip.2021.04.064
3. Chu AWL, Wong MM, Rayner DG, et al. Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1470-1492. doi:10.1016/j.jaci.2023.08.029
4. Chu DK, Schneider L, Asiniwasis RN, et al; AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274-312. doi:10.1016/j.anai.2023.11.009
Related to this article








